Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Propanc Biopharma, Inc.

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates “Unprecedented” Interest
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Notice of Allowance for “Proenzyme Composition” Patent in North America
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Certificate of Grant for “Proenzymes Composition” Patent from Japanese Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces Strategic Pharma Partnering Initiative
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCBD
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCBD
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces Reverse Stock Split
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Provides Shareholder Update
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
From Propanc Biopharma, Inc.
Via Business Wire
Tickers OTC PPCB
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program
From Propanc Biopharma, Inc.
Via Business Wire
Tickers PPCB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.